Tandem Diabetes Care has lost two-thirds of its market value this year, and executives have partially blamed the inability of many Americans to afford its potentially life-saving technology.
Tandem Diabetes Care Inc. shares plummeted more than 20% after the company reported earnings Wednesday, continuing a decline that has already cost the company two-thirds of its market value this year and has been partially blamed on the inability of many Americans to afford the potentially life-saving technology.
“Our data suggests that this dynamic began impacting new customers’ decision to purchase the pump beginning in the second quarter. This is primarily a factor in the U.S., as outside the United States, it’s mitigated by the predominance of government healthcare plans,” he said at the time. The problems have landed on Tandem’s revenue growth rates and forecasts. In Wednesday’s third-quarter results, Tandem reported that sales grew to $205.1 million from $179.6 million, missing analysts’ average estimate of $207.6 million, according to FactSet. Analysts had already shed about $10 million from that estimate after disappointing results last quarter.
Tandem’s forecast suggests that executives expect the U.S. to account for nearly 75% of its sales this year. Executives hope to find more business outside the U.S. as well, launching the business in Israel and Portugal in the third quarter, which Sheridan said brings the number of countries in which Tandem sells its t:slim X2 device to 25.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Nottinghamshire care home rated inadequate by inspectors is closedA care home manager resigned during a Care Quality Commission (CQC) inspection.
Baca lebih lajut »
A New and Improved Diabetes DrugTirzepatide, a new diabetes drug administered weekly through injection, helped those with type 2 diabetes meet blood glucose goals 4 to 12 weeks earlier than those receiving conventional diabetic drugs. The phase 3 SURPASS trials, which were published in 2021, proved that tirzepatide reduces bloo
Baca lebih lajut »
What to Know About Diabetes and the Risk of Silent Heart AttacksSilent heart attacks, which are more common in people with diabetes, don’t cause typical or obvious symptoms
Baca lebih lajut »
What to Know About Bariatric Surgery for Type 2 DiabetesResearch indicates that surgery can put diabetes into remission, and it’s safe and cost-effective
Baca lebih lajut »
National Diabetes Month 2022 | NIDDKWe're teaming up with NIDDKgov this National DiabetesMonth because it takes a team to manage diabetes. Health care professionals can offer the personal care you need to improve your overall health. Find out more:
Baca lebih lajut »